Previous Close | 2.7500 |
Open | 2.7500 |
Bid | 3.1000 |
Ask | 4.1000 |
Strike | 20.00 |
Expire Date | 2024-09-20 |
Day's Range | 2.7500 - 2.7500 |
Contract Range | N/A |
Volume | |
Open Interest | 21 |
On June 26, 2024, Ying Du, Chairperson & CEO of Zai Lab Ltd (NASDAQ:ZLAB), executed a sale of 23,939 shares of the company, according to the SEC Filing. Zai Lab Ltd (NASDAQ:ZLAB) is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for cancer, autoimmune, and infectious diseases. Over the past year, Ying Du has sold a total of 38,106 shares of Zai Lab Ltd and has not made any purchases of the stock.
Key Insights Zai Lab's Annual General Meeting to take place on 18th of June CEO Samantha Du's total compensation...
SHANGHAI & CAMBRIDGE, Mass., June 11, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced today that following a distinguished career, Harald Reinhart, M.D., President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases (NSAiID) of Zai Lab, will retire at the end of June, after which he will serve as a senior advisor for the Company. Rafael Amado, M.D., President, Head of Global Oncology Research and Development of Zai Lab, will expand his role and assume respons